Novel vaccines for the treatment of gastrointestinal cancers

ONCOLOGY

Volumn 19, Issue 12, 2005, Pages 1557-1565

  Marshall, John L ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METRONIDAZOLE; MUCIN 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE; VIRUS VACCINE;

ANTIGENICITY; AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNIZATION; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; INJECTION SITE REACTION; LUNG CANCER; POXVIRUS; REVIEW; T LYMPHOCYTE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; FORECASTING; GASTROINTESTINAL TUMOR; MALE; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I; DISEASE MODELS, ANIMAL; FEMALE; FORECASTING; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644861112     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Coley WB: A report of recent cases of inoperable sarcoma successfully treated with mixed toxins of erysipelas and Bacillus prodigiosus. Surg Gynecol Obstet 13:174-190, 1911.
2. Gilboa E: The promise of cancer vaccines. Nat Rev Cancer 4:401-411, 2004.
3. Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769-778, 1957.
4. Tian J, Olcott AP, Kaufman DL: Antigen-based immunotherapy drives the precocious development of autoimmunity. J Immunol 169:6564-6569, 2002.
5. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27, 1970.
6. Alexander P: Innate resistance and specific immunity in host control of cancer. J Med 8:279-285, 1977.
7. Mukherji B, Chakraborty NG, Sivanandham M: T-cell clones that react against autologous human tumors. Immunol Rev 116:33-62, 1990.
8. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574-583, 2000.
9. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
10. Bethge WA, Hegenbart U, Stuart MJ, et al: Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103:790-795, 2004.
11. Cheson BD: What is new in lymphoma? CA Cancer J Clin 54:260-272, 2004.
12. Nagorsen D, Scheibenbogen C, Marincola FM, et al: Natural T cell immunity against cancer. Clin Cancer Res 9:4296-4303, 2003.
13. Boon T, Kellermann O: Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A 74:272-275, 1977.
14. Boon T, Van Pel A: Teratocarcinoma cell variants rejected by syngeneic mice: Protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A 75:1519-1523, 1978.
15. Van Pel A, Georlette M, Boon T: Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: Immune rejection by syngeneic mice. Proc Natl Acad Sci U S A 76:5282-5285, 1979.
16. Tsuruma T, Hata F, Torigoe T, et al: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2:19, 2004.
17. Zelle-Rieser C, Barsoum AL, Sallusto F, et al: Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. J Urol 165:1705-1709, 2001.
18. Minev B, Hipp J, Firat H, et al: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 97:4796-4801, 2000.
19. Caligiuri MA, Velardi A, Scheinberg DA, et al: Immunotherapeutic approaches for hematologic malignancies. Hematology (Education Program Book) 337-353, 2004.
20. Lyerly HK: Quantitating cellular immune responses to cancer vaccines. Semin Oncol 30(3 suppl 8):9-16, 2003
21. Whiteside TL, Zhao Y, Tsukishiro T, et al: Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 9:641-649, 2003.
22. Marshall J: Carcinoembryonic antigen-based vaccines. Semin Oncol 30(suppl 8):30-36, 2003.
23. Greiner JW, Zeytin H, Anver MR, et al: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62:6944-6951, 2002.
24. Horig H, Medina FA, Conkright WA, et al: Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert Rev Mol Med 2000:1-24, 2000.
25. Kass E, Schlom J, Thompson J, et al: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 59:676-683, 1999.
26. Mizobata S, Tompkins K, Simpson JF, et al: Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 49:285-295, 2000.
27. Stevanovic S: Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2:514-520, 2002.
28. Kawashima I, Tsai V, Southwood S, et al: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59:431-435, 1999.
29. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996.
30. Zaremba S, Barzaga E, Zhu M, et al: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570-4577, 1997.
31. Salazar E, Zaremba S, Arlen PM, et al: Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 85:829-838, 2000.
32. Palena C, Schlom J, Tsang KY: Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. Clin Cancer Res 9:1616-1627, 2003.
33. Peterson FC, Elgin ES, Nelson TJ, et al: Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem 279:12598-12604, 2004.
34. Waterhouse NJ, Sedelies KA, Clarke CJ: Granzyme B; the chalk-mark of a cytotoxic lymphocyte. J Transl Med 2:36, 2004.
35. Kerr D: Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 3:615-622, 2003.
36. Johnson LG: Gene therapy for cystic fibrosis. Chest 107(2 suppl):77S-83S, 1995.
37. Eto Y, Gao JQ, Sekiguchi F, et al: Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol Pharm Bull 27:936-938, 2004.
38. Kaufman H, Schlom J, Kantor J: A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 48:900-907, 1991.
39. Mackett M, Smith GL, Moss B: General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49:857-864, 1984.
40. Tsang KY, Zaremba S, Nieroda CA, et al: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982-990, 1995.
41. Hodge JW, McLaughlin JP, Kantor JA, et al: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15:759-768, 1997.
42. Tartaglia J, Perkus ME, Taylor J, et al: NYVAC: A highly attenuated strain of vaccinia virus. Virology 188:217-232, 1992.
43. Taylor J, Meignier B, Tartaglia J, et al: Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13:539-549, 1995.
44. Marshall JL, Hawkins MJ, Tsang KY, et al: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332-337, 1999.
45. Marshall JL, Hoyer RJ, Toomey MA, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964-3973, 2000.
46. Marshall J, Tsang KY, Arlen P, et al: Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-cSF and IL-2 to the combination of vaccinia-CEA and ALVAC-CEA administered as a prime and boost in patients with advanced CEA-bearing cancers (abstract 1087). Proc Am Soc Clin Oncol 20:272a, 2001.
47. Song SY, Kim HS: Strategies to improve dendritic cell-based immunotherapy against cancer. Yonsei Med J 45(suppl):48-52, 2004.
48. Fong L, Hou Y, Rivas A, et al: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809-8814, 2001.
49. Alters SE, Gadea JR, Philip R: Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 417:519-524, 1997.
50. Alters SE, Gadea JR, Sorich M, et al: Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 21:17-26, 1998.
51. Morse MA, Nair SK, Mosca PJ, et al: Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 21:341-349, 2003.
52. Disis ML, Bernhard H, Shiota FM, et al: Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88:202-210, 1996.
53. Jager E, Ringhoffer M, Dienes HP, et al: Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62, 1996.
54. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993.
55. Nemunaitis J, Sterman D, Jablons D, et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96:326-331, 2004.
56. Ueda Y, Itoh T, Nukaya I, et al: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 24:909-917, 2004.
57. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, et al: Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 10:3273-3281, 2004.
58. Kass E, Panicali DL, Mazzara G, et al: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61:206-214, 2001.
59. Hodge JW, McLaughlin JP, Abrams SI, et al: Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 55:3598-3603, 1995.
60. von Mehren M, Arlen P, Gulley J, et al: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7:1181-1191, 2001.
61. Hodge JW, Sabzevari H, Yafal AG, et al: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59:5800-5807, 1999.
62. Hesdorffer C, Hoerig H, Deraffele G, et al: Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma (abstract 7504). J Clin Oncol 23(14S):708, 2004.
63. Grosenbach DW, Barrientos JC, Schlom J, et al: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 61:4497-4505, 2001.
64. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, et al: Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy. Cancer Gene Ther 11:665-680, 2004.
65. Morse MA, Clay TM, Hobeika AC, et al: Phase I study of immunization with dendritic cells modified with recombinant fowlpox encoding carcinoembryonic antigen and the trial of costimulatory molecules CD54, CD58, CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies (abstract 2508). J Clin Oncol 22(14S):165, 2004.
66. Aarts WM, Schlom J, Hodge JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 62:5770-5777, 2002.
67. Marshall J, Arlen P, Rizvi N, et al: A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA expressing carcinomas (abstract 24). Proc Am Soc Clin Oncol 21:7a, 2002.
68. Marshall J, Odogwu L, Hwang J, et al: A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7/ICAM/ LFA3) alone, and in combination with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA expressing carcinomas (abstract 662). Proc Am Soc Clin Oncol 22:165, 2003.
69. Marshall JL, Gulley JL, Arlen PM, et al: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720-731, 2005.
70. Byrd JC, Bresalier RS: Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 23:77-99, 2004.
71. Tsang KY, Palena C, Gulley J, et al: A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 10:2139-2149, 2004.
72. Kaufman H, Dipaola R, von Mehren M, et al: Safety profile of therapeutic pox virus-based vaccines for cancer (abstract 2513). J Clin Oncol 23(14S):166, 2004.
73. Schuetz T, Marshall J, Kaufman H, et al: Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer (abstract 2564). J Clin Oncol 22(14S):179, 2004.
74. Chakraborty M, Abrams SI, Coleman CN, et al: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328-4337, 2004.
75. Garnett CT, Palena C, Chakraborty M, et al: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985-7994, 2004.
76. Belardelli F, Ferrantini M, Parmiani G, et al: International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 64:6827-6830, 2004.